OverviewSuggest Edit

Nouscom develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The Company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses.

TypePrivate
Founded2015
HQBasel, CH
Websitenouscom.com

Latest Updates

Employees (est.) (Apr 2022)34(+4%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Nouscom

Riccardo Cortese

Riccardo Cortese

Co-Founder
Elisa Scarselli

Elisa Scarselli

Chief Scientific Officer and Co-Founder
Marina Udier

Marina Udier

Chief Executive Officer & Board Director
Stefano Colloca

Stefano Colloca

Co-Founder & Advisor
Tiffany Muller

Tiffany Muller

VP, Finance
Patricia Delaite

Patricia Delaite

Chief Medical Officer
Show more

Nouscom Office Locations

Nouscom has offices in Basel and Roma
Basel, CH (HQ)
18 Bäumleingasse
Roma, IT
100 Via di Castel Romano
Show all (2)

Nouscom Financials and Metrics

Summary Metrics

Founding Date

2015

Nouscom total Funding

$62.6 m

Nouscom latest funding size

$49 m

Time since last funding

5 years ago

Nouscom investors

Nouscom's latest funding round in November 2017 was reported to be $49 m. In total, Nouscom has raised $62.6 m
Show all financial metrics

Nouscom Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Nouscom Online and Social Media Presence

Embed Graph

Nouscom News and Updates

Nouscom to present interim data from Phase 1 trial evaluating NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine for the treatment of MSI-H solid tumors

BASEL, Switzerland, Nov. 10, 2021 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announced that promising interim safety, immunogenicity, pharmacokinetic, pharmacodynamic, and clinical activity...

Nouscom announces initial results from Phase 1 trial for NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine, in MSI-H solid tumors

BASEL, Switzerland, Sept. 16, 2021 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announced initial results from the Phase 1 trial of NOUS-209, the first clinical results for the company....

Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer

BASEL, Switzerland, Aug. 24, 2021 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announced that the first patient has been dosed in a Phase 1b clinical trial evaluating NOUS-PEV. In this...

Nouscom highlights innovative science behind VENUS, its novel algorithm for identifying and prioritizing patient-specific tumor neoantigens for personalized cancer immunotherapy

BASEL, Switzerland, Aug, 10, 2021 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announces the online publication of new research describing its novel and proprietary algorithm for the...

Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy

BASEL, Switzerland, March 11, 2021 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology biotech developing next generation viral-vector based immunotherapies, today announces it has received approval from the Spanish National Agency of Medicines and Medical Devices (Agencia Española...

Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer

BASEL, Switzerland, Dec. 11, 2020 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized genetic cancer vaccines, today announces that it has appointed Göran Ando, MD as the new Chairman of its Board of Directors. Nouscom also appointed...
Show more

Nouscom Blogs

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed using Nouscom’s Proprietary Viral Vector Platform

VAC85135 is a novel clinical candidate developed by Nouscom and Janssen under a multi-project agreement BASEL, Switzerland – 17th May 2022 – Nouscom, a clinical stage immuno-oncology company developing both off-the-shelf and personalized cancer neoantigen immunotherapies, today announced that Jansse…

Nouscom Announces New Translational Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022

BASEL, Switzerland – 11th April 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced encouraging new translational data obtained from the ongoing Phase 1 trial evaluating NOUS-209. The data were presented y…

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

Nouscom recently published in the Journal for ImmunoTherapy of Cancer a manuscript entitled: “Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion” (D’Alise AM, Leoni G, De Lucia M, et al reference below). The manuscr…

Nouscom to present interim data from Phase 1 trial evaluating NOUS-209, an ‘off-the-shelf’ neoantigen cancer vaccine for the treatment of MSI-H solid tumors

Results presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting BASEL, Switzerland – 10th November 2021 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announced that promising interim safety, immunoge…

Nouscom AG: Abstract on interim results from Phase 1 trial for NOUS-209, an “off-the-shelf” neoantigen cancer vaccine, in MSI-H solid tumors will be presented at SITC

Our abstract “Phase 1 Interim Study Results of Nous-209, an Off-the-Shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite Instability (dMMR/MSI-H)” will be presented by Dr Dung Le, MD, The John Hopkins University, a Senior Investiga…

Dr. Elisa Scarselli will join as Expert Speaker at the virtual Neoantigen Based Therapies Summit

Our Co-Founder and CSO Dr. Elisa Scarselli will join as Expert Speaker at the virtual Neoantigen Based Therapies Summit from October 26 – 28, 2021. Find out more about the conference and register here: Register – 6th Neoantigen Based Therapies US Summit 2021 (neo-antigen.com) L'articolo Dr. Elisa Sc…
Show more

Nouscom Frequently Asked Questions

  • When was Nouscom founded?

    Nouscom was founded in 2015.

  • Who are Nouscom key executives?

    Nouscom's key executives are Riccardo Cortese, Elisa Scarselli and Marina Udier.

  • How many employees does Nouscom have?

    Nouscom has 34 employees.

  • Who are Nouscom competitors?

    Competitors of Nouscom include Stealth BioTherapeutics, Talaris Therapeutics and Fauna Bio.

  • Where is Nouscom headquarters?

    Nouscom headquarters is located at 18 Bäumleingasse, Basel.

  • Where are Nouscom offices?

    Nouscom has offices in Basel and Roma.

  • How many offices does Nouscom have?

    Nouscom has 2 offices.